WP5 investigates whether FDG-PET/CT-based monitoring approaches are not only clinically effective but also cost-effective and equitable. Led by the Institute of Public Health, Medical Decision Making and Health Technology Assessment at UMIT TIROL, this work package performs cost-effectiveness analyses alongside the MONITOR-RCT trial and develops a decision-analytic model to assess long-term benefits, harms, costs, and equity across different healthcare systems.
The findings aim to inform evidence-based health policy recommendations, ensuring that advanced imaging strategies can be implemented efficiently and sustainably within European healthcare. By combining clinical and economic perspectives, WP5 helps ensure that innovations from PREMIO COLLAB lead to better patient outcomes and smarter use of healthcare resources.